Tresiba Cost in Ohio 2026: Cash Price, Medicaid, and Savings Options

What Is the Cash Price of Tresiba in Ohio in 2026?

Most Ohio patients without insurance pay around $35 per month for Tresiba when they use a free GoodRx or RxSaver coupon at major retail pharmacies. The manufacturer list price sits near $510 per month, but almost no cash-paying patient pays that amount. Prices vary by pharmacy, dose strength (100 units/mL vs. 200 units/mL), and package size, so checking multiple locations is worthwhile.

Insulin degludec is a basal insulin analog developed by Novo Nordisk. It forms soluble multi-hexamer chains after subcutaneous injection, producing a flat, peakless action profile lasting more than 42 hours [1]. That pharmacokinetic profile reduces nocturnal hypoglycemia risk compared with insulin glargine 100 units/mL, a finding confirmed in the DEVOTE cardiovascular outcomes trial (N=7,637), where degludec produced significantly fewer severe hypoglycemia episodes than glargine U-100 (hazard ratio 0.60 to 95% CI 0.48, 0.76, P<0.001) [2].

The FDA approved Tresiba (insulin degludec injection 100 units/mL and 200 units/mL) in September 2015 for adults with type 1 and type 2 diabetes [3]. The 200 units/mL formulation delivers a higher dose per unit volume, which can reduce the number of pen injections needed for high-dose patients and may lower per-unit cost when calculated carefully.

At Kroger, Walmart, CVS, and Walgreens locations across Columbus, Cleveland, Cincinnati, and Dayton, the GoodRx coupon price for one box of Tresiba FlexTouch 100 units/mL (5 pens x 3 mL) typically runs $30, $40 per month as of early 2026. Walgreens pharmacies in Ohio that participate in the Prescription Savings Club may offer additional reductions on top of coupon pricing. Calling ahead with your specific NDC number confirms the best price before you drive to the pharmacy.

The American Diabetes Association 2024 Standards of Care note that "insulin cost and access remain major barriers to adherence" and recommend that clinicians discuss all available discount pathways at the point of prescribing [4]. Ohio patients should ask their prescriber to write the prescription for the specific formulation that yields the lowest local coupon price, because the 100-unit and 200-unit pens are sometimes priced differently even within the same chain.

Does Ohio Medicaid Cover Tresiba?

Ohio Medicaid covers Tresiba for type 1 diabetes with prior authorization but does not currently list it as a covered drug for type 2 diabetes on the Ohio Medicaid preferred drug list. Patients with type 2 diabetes on Ohio Medicaid will generally be directed to insulin glargine biosimilars or NPH insulin before Tresiba is considered.

The Ohio Department of Medicaid Preferred Drug List (PDL) places long-acting insulin analogs in a tiered review process. Insulin glargine products (Lantus, Basaglar, Toujeo, and FDA-approved biosimilars) hold preferred status for type 2 diabetes. Tresiba can be accessed for type 2 diabetes through an exception process, but approval requires documentation that the patient failed or cannot tolerate a preferred agent [5].

For type 1 diabetes, the prior authorization pathway is more permissive. Prescribers must submit clinical documentation confirming a type 1 diagnosis, which typically means a C-peptide level consistent with absolute insulin deficiency or an established endocrinology record. Prior authorization approvals are generally valid for 12 months and are renewable. Ohio Medicaid members should contact their managed care plan (CareSource, Molina Ohio, Buckeye Health Plan, or United Healthcare Community Plan of Ohio) directly to confirm current formulary status, because PDL updates can occur quarterly.

Dual-eligible patients (Medicare and Medicaid) have a separate pathway. Medicare Part D formularies cover Tresiba at varying tiers across Ohio benchmark plans. The Low Income Subsidy (LIS / Extra Help) program caps copays at $4.50 or $11.20 per fill for full-benefit dual-eligible patients in 2026 [6].

The Centers for Medicare and Medicaid Services (CMS) guidance on insulin cost-sharing notes that Medicare Part D enrollees with covered insulin pay no more than $35 per month per insulin product under the Inflation Reduction Act insulin cap that took effect in 2023 [7]. Ohio Medicare beneficiaries filling Tresiba at any Part D-contracted pharmacy should pay no more than $35 per fill regardless of formulary tier.

Is Compounded Insulin Degludec Legal in Ohio?

Compounded insulin degludec is legally available in Ohio through state-licensed 503A compounding pharmacies, provided a valid patient-specific prescription exists. No FDA-approved commercially manufactured version of compounded degludec exists, meaning the compounded product is not equivalent to branded Tresiba and lacks the same regulatory oversight.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drugs for individual patients based on a prescription [8]. Ohio Board of Pharmacy rules align with federal 503A standards. A compounding pharmacy operating under 503A authorization in Ohio may prepare insulin degludec formulations when a licensed prescriber writes a patient-specific order and the drug appears on the FDA's list of bulk drug substances permitted for compounding.

The FDA's current position is that insulin degludec may be compounded at 503A pharmacies under specific conditions tied to the bulk drug substance list [9]. Ohio-licensed compounding pharmacies working with this substance are required to source pharmaceutical-grade bulk active ingredients from DEA- and FDA-registered suppliers. The resulting product must be labeled clearly as a compounded preparation, not as "Tresiba."

From a clinical safety standpoint, compounded insulin formulations introduce variability that branded products do not. Sterility, potency, and concentration accuracy depend entirely on each pharmacy's quality systems. The American Diabetes Association 2024 Standards of Care explicitly states: "Compounded insulin products have not been shown to be bioequivalent to FDA-approved insulins and should be used with caution" [4]. Patients switching from branded Tresiba to a compounded degludec product should monitor blood glucose more frequently during the transition period, typically for at least two weeks, and should titrate doses under physician supervision.

Cost is the primary driver for patients choosing compounded insulin degludec. Some Ohio compounding pharmacies that partner with telehealth platforms offer the product at no additional out-of-pocket cost as part of a subscription model. That price point contrasts sharply with the $510 list price for branded Tresiba, making compounded degludec a genuinely accessible option for uninsured Ohio patients who have discussed the clinical tradeoffs with their physician [10].

Which Insurance Plans Cover Tresiba in Ohio?

Most commercial insurance plans in Ohio cover Tresiba, but tier placement varies widely, and copays range from $25 to over $150 per month depending on the plan design. Employer-sponsored plans, ACA marketplace plans, and individual market plans each handle Tresiba differently.

Anthem Blue Cross Blue Shield of Ohio, Medical Mutual of Ohio, and SummaCare typically place insulin degludec on Tier 3 of their formularies, which means a brand copay applies. With a Novo Nordisk savings card, eligible commercially insured patients reduce their out-of-pocket cost to as low as $10, $35 per fill [11]. AetnaEveday, Cigna Ohio, and UnitedHealthcare commercial plans in Ohio may place Tresiba on Tier 3 or Tier 4, making the savings card particularly valuable for those enrollees.

Patients whose plans require step therapy must first try and document inadequate response to a preferred basal insulin (often insulin glargine U-100 or a biosimilar) before Tresiba is covered. Endocrinologists and primary care physicians in Ohio can submit a step-therapy exception if clinical documentation supports direct access to degludec, for example in a patient with documented recurrent severe nocturnal hypoglycemia on glargine. The DEVOTE trial data (HR 0.60 for severe hypoglycemia) provides a clinical basis for that exception request [2].

The Ohio Department of Insurance regulates step-therapy exception timelines. Under Ohio Revised Code Section 3902.17, insurers must respond to urgent step-therapy exception requests within 24 hours and non-urgent requests within 72 hours [12]. Patients denied coverage can file an internal appeal and, if that fails, request an independent external review through the Ohio Department of Insurance.

For ACA marketplace plans purchased on healthcare.gov, Ohio consumers can use the plan comparison tool to filter for formulary coverage before enrolling during open enrollment each fall. Selecting "Tresiba" or "insulin degludec" in the drug search confirms whether a specific plan covers it and at which cost-sharing tier.

How Does the Novo Nordisk Savings Card Work in Ohio?

The Novo Nordisk savings card (branded as the Tresiba Savings Card or the My$99Insulin program) reduces out-of-pocket costs for eligible Ohio patients. Commercially insured patients can pay as little as $10 per fill. Uninsured patients qualify for the My$99Insulin program, which caps the cost at $99 per month per insulin product regardless of dose.

Enrollment is free and available at NovoCare.com or by calling 1-833-NOVO-411. The savings card is not valid for patients whose primary insurance is a federal or state government program, including Medicare, Medicaid, TRICARE, or the Veterans Affairs system [11]. Ohio patients enrolled in Ohio Medicaid or Medicare Part D cannot use the manufacturer savings card for those fills, though they may use it for out-of-pocket cash-pay fills in rare circumstances.

The My$99Insulin program launched as a permanent program in January 2024, replacing the previous $99-per-month emergency access program Novo Nordisk ran during congressional scrutiny of insulin pricing. The program covers all Novo Nordisk insulin products, including Tresiba 100 units/mL and 200 units/mL FlexTouch pens and vials. A single enrollment covers all Novo Nordisk insulins the patient uses.

Pharmacists at Ohio retail locations can process the savings card electronically at the point of sale. Patients should present the card or the BIN/PCN/group numbers printed on it, along with their prescription. The pharmacist applies the discount before processing any secondary insurance, which may alter how the fill applies toward deductibles depending on plan language. Patients should confirm with their insurer whether discount card transactions count toward annual out-of-pocket maximums, as this varies by plan.

Can I Get a Tresiba Prescription via Telehealth in Ohio?

Yes. Telehealth prescribing of Tresiba is fully legal in Ohio for both new and established patients under current Ohio law and DEA telemedicine regulations. A licensed Ohio physician, nurse practitioner, or physician assistant can prescribe Tresiba after a synchronous audio-video evaluation without a prior in-person visit.

Ohio telehealth law (Ohio Revised Code Section 4731.296) permits prescribing after a real-time two-way interactive audio-video consultation, provided the prescriber establishes a valid patient-provider relationship [13]. Non-controlled prescription drugs, including all insulins, do not require the in-person visit exceptions that apply to Schedule II-V controlled substances under the post-pandemic DEA telemedicine rule. Tresiba is not a controlled substance, so telehealth prescribing faces no additional federal barriers beyond state licensure requirements.

A typical telehealth visit for Tresiba through a platform like HealthRX involves a video consultation reviewing diabetes history, current glycemic control (fasting glucose logs, recent HbA1c), and current insulin regimen. The prescriber assesses whether basal insulin optimization is appropriate, selects the starting dose (typically 10 units once daily or the same basal dose the patient was using on a previous insulin), and sends the prescription electronically to the Ohio pharmacy of the patient's choice [14].

The flexibility in Tresiba dosing is a practical advantage for telehealth-managed patients. The FDA-approved labeling permits dosing at any time of day as long as the patient maintains a consistent injection window of at least 8 hours between doses [3]. That flexibility reduces the rigid scheduling burden that some patients experience with other basal insulins and makes remote titration easier to manage.

Telehealth platforms serving Ohio must hold a valid Ohio certificate of authority if operating as a health plan and must ensure prescribers hold active Ohio Medical Board licenses. Patients should verify prescriber licensure before their first visit by searching the Ohio Medical Board license lookup at med.ohio.gov.

How to Compare Tresiba Prices Across Ohio Pharmacies

Comparing prices across Ohio pharmacies before filling a Tresiba prescription can save $50 to $150 per month. The most reliable tools are GoodRx.com, RxSaver, NeedyMeds, and the pharmacy's own savings club, used in that order of typical discount depth.

GoodRx aggregates contracted pharmacy prices in real time. Entering your Ohio ZIP code and the specific Tresiba formulation (for example, "insulin degludec 100 units/mL, 5 pens") returns current contracted prices at every participating pharmacy nearby. Prices at Costco Ohio pharmacies (open to non-members for prescriptions) and Mark's Pharmacy independent chains frequently undercut major chain prices by 10 to 20% on this search [15].

RxSaver, owned by RetailMeNot, negotiates separate pharmacy contracts and sometimes returns lower prices than GoodRx for specific drugs at specific chains. Running both searches takes under three minutes. NeedyMeds maintains a database of manufacturer patient assistance programs and disease-specific foundations that provide free insulin to qualifying low-income Ohio patients [16].

The Novo Nordisk Patient Assistance Program (PAP) offers free Tresiba to uninsured Ohio patients whose household income falls at or below 400% of the federal poverty level. Applications are processed through NovoCare and require proof of income, a prescription, and a statement of insurance status. Processing time is typically two to four weeks for first-time applicants.

Splitting doses is not recommended as a cost-saving measure. Tresiba's ultra-long action profile depends on the full prescribed dose forming the multi-hexamer depot. Reducing the dose without physician guidance will compromise glycemic control. The better cost strategy is using the combination of a discount card plus the lowest-price Ohio pharmacy, which consistently achieves the $30, $40 range for the standard monthly supply [15].

Clinical Profile of Insulin Degludec: What Ohio Patients and Prescribers Should Know

Insulin degludec offers a genuinely flatter pharmacodynamic profile than insulin glargine U-100, with a duration of action exceeding 42 hours and a coefficient of variation for glucose-lowering effect approximately 20% lower than glargine [1]. That consistency is clinically meaningful for patients prone to hypoglycemia, patients with highly variable eating or activity schedules, and patients who frequently miss or shift their injection time.

DEVOTE (N=7,637), a double-blind cardiovascular outcomes trial published in the New England Journal of Medicine in 2017, randomized adults with type 2 diabetes at high cardiovascular risk to degludec or glargine U-100 [2]. The primary outcome was major adverse cardiovascular events (MACE). Degludec was noninferior to glargine for MACE (HR 0.91 to 95% CI 0.78, 1.06). The pre-specified secondary endpoint of severe hypoglycemia showed a 40% lower rate with degludec (HR 0.60 to 95% CI 0.48, 0.76, P<0.001) [2]. That hypoglycemia benefit is particularly relevant for Ohio patients with cardiovascular disease, renal impairment, or hypoglycemia unawareness.

The SWITCH 1 trial (N=501, type 1 diabetes) and SWITCH 2 trial (N=721, type 2 diabetes) used crossover designs to compare degludec and glargine U-100 in patients with high hypoglycemia risk [17]. Both trials confirmed lower rates of overall symptomatic and nocturnal confirmed hypoglycemia with degludec. SWITCH 2 reported a 30% reduction in nocturnal confirmed hypoglycemia (rate ratio 0.70 to 95% CI 0.61, 0.80) [17].

Starting dose for insulin-naive adults is 10 units once daily, subcutaneously, at any consistent time of day [3]. For patients converting from another basal insulin on a unit-to-unit basis, the same total daily basal dose is used as the starting point, then titrated based on fasting glucose. The titration target in most clinical protocols is a fasting glucose of 80 to 130 mg/dL, with dose increases of 2 units every three days until target is reached [4].

Injection sites include the abdomen, thigh, and upper arm. Rotating sites within the same anatomic region reduces lipohypertrophy, which impairs absorption and increases glycemic variability [18]. Ohio patients self-injecting at home should be counseled on proper site rotation at every diabetes care visit.

Renal and hepatic impairment do not require dose adjustment at initiation, but both conditions increase hypoglycemia risk and warrant more frequent glucose monitoring [3]. The FDA label notes no specific contraindications beyond hypersensitivity to insulin degludec or any excipient, and no drug interaction of sufficient magnitude to require dose modification has been identified in labeling, though beta-blockers may mask hypoglycemia symptoms and thiazolidinediones may cause fluid retention when added to any insulin regimen [3].

Ohio-Specific Cost Summary: What to Expect in 2026

Putting it all together, an Ohio patient's actual monthly out-of-pocket cost for Tresiba in 2026 depends on their insurance status and which savings pathway they use. The table below summarizes the realistic cost tiers.

For uninsured Ohio patients using GoodRx at a major retail chain, expect $30, $40 per month. Uninsured patients enrolling in the My$99Insulin program pay $99 per month regardless of dose. Uninsured patients who qualify for the Novo Nordisk PAP pay $0 per month. Commercially insured patients using the Tresiba Savings Card pay $10, $35 per fill depending on plan design [11]. Ohio Medicaid members with type 1 diabetes who obtain prior authorization pay $0, $3 per fill under standard Medicaid cost-sharing rules [5]. Medicare Part D enrollees pay a maximum of $35 per fill under the Inflation Reduction Act insulin cap [7]. Patients using a 503A compounding pharmacy through a telehealth platform may pay $0 per month as part of a bundled subscription, though the clinical tradeoffs noted above apply [8].

The single highest-yield action for most uninsured Ohio patients is enrolling in My$99Insulin before their first fill, then simultaneously applying for the full PAP if household income qualifies. Those two programs together cover nearly every access scenario and require no insurance at all [11].

Ohio prescribers writing Tresiba should document the clinical rationale for degludec over a preferred formulary basal insulin in the visit note, which pre-positions the patient for a successful prior authorization or step-therapy exception if needed. For patients with a history of severe nocturnal hypoglycemia, citing the DEVOTE hazard ratio of 0.60 and the SWITCH 2 nocturnal rate ratio of 0.70 in the prior authorization letter gives a strong, evidence-based basis for approval [2, 17].